Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...

These jabs work by providing an instruction to the patient’s cells to churn out a particular protein that acts as a flag for ...

Collaboration will Leverage Solidion's Patent Portfolio and Drive U.S. Manufacturing DALLAS, Nov. 11, 2024 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI), an advanced battery technology ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

Application error: a client-side exception has occurred (see the browser console for more information).

European markets are expected to start the week on a mostly positive note Monday, with all eyes on Tuesday's presidential ...

KAOHSIUNG, TAIWAN – Contrary to what much of the world’s media has reported, China’s 13-hour simulated blockade of Taiwan that began on Monday, Oct. 14, using a record-breaking number of ...

Soldiers must "enhance their strategic deterrent and combat capability," Xi said. China, which claims Taiwan as part of its territory, has stepped up its shows of force around the self-ruled ...

Could SEAL Team 6 special operators help Taiwan fend off a Chinese invasion? That is what the elite special operations unit has been preparing for over a year, according to recent reporting from ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

South Africans need to be in the know if we want to create a prosperous future. News24 has kept the country informed for 25 years, and we're about to enter a new chapter of fearless journalism. Join ...